fda approved oral semaglutide New Dosage Forms by Novo Nordisk's weight-loss pill wins

Phase 3 SURPASS trials began in 2019

Eli Lillys Phase 3 TRIUMPH-4 trial (December 2025) reported that participants taking 12mg of Retatrutide over 68 weeks lost an average of 28.7% of their body weight, the highest result ever reported at that stage for any obesity-related compound

Because Retatrutide targets more receptors, it may cause different or additional side effects, but more data is needed

Sunlight reports 100,000+ patients served, based on self-reported data

Those in Florida looking for semaglutide weight loss options will find Wegovy a beneficial choice, as clinical trials demonstrate significant effectiveness, leading to about 15% body weight loss over 68 weeks